Edit
Vigilant Biosciences, Inc.
http://www.vigilantbiosciences.com/Last activity: 09.09.2020
Probably Closed
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention.
The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer.
The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States.
Leadership:
Bill Brodie, Chief Executive Officer
Robert T. Hamilton, CPA, Chief Financial Officer
Dragan Nebrigic, Ph.D., Chief Operating Officer
Ben Beckham, Chief Commercial Officer
Michael Donovan, M.D. Ph.D., Chief Clinical Officer
Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Kris Foss, Vice President, Regulatory, Quality & Clinical
The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer.
The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States.
Leadership:
Bill Brodie, Chief Executive Officer
Robert T. Hamilton, CPA, Chief Financial Officer
Dragan Nebrigic, Ph.D., Chief Operating Officer
Ben Beckham, Chief Commercial Officer
Michael Donovan, M.D. Ph.D., Chief Clinical Officer
Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Kris Foss, Vice President, Regulatory, Quality & Clinical
Location: United States, Florida, Fort Lauderdale
Employees: 11-50
Phone: +1 305-728-5382
Total raised: $16M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | White Owl ... | whiteowlca... |
| - | Florida In... | florida-in... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.07.2016 | Series B | $10.5M | - |
| 24.02.2015 | Series B | $5.5M | - |
Mentions in press and media 12
| Date | Title | Description |
| 09.09.2020 | Vigilant Biosciences Announces New Website Launch | |
| 31.01.2020 | Investors in the house at FVCC, and Florida startups were in the spotlight | Facebook Tweet Pin LinkedIn Email By Nancy Dahlberg Macro economic indicators may be signaling a possible downturn and venture pullback ahead, but the mood at the 2020 Florida Venture Capital Conference in Orlando this week was decidedly bu... |
| 14.01.2020 | South Florida’s 2019 was a record-buster for VC. Who raised in Q4? | Facebook Tweet Pin LinkedIn Email South Florida snagged $2.37 billion in venture capital in 2019, according to the Venture Monitor report released Tuesday. That’s a record and it ranks the metro area No. 7 in the nation. By Nancy Dahlberg F... |
| 11.07.2016 | Vigilant Biosciences raises $10.5M in Series B round | The money will be used in commercialization efforts, especially to make the Fort Lauderdale, Florida company’s OncAlert Oral Cancer product line available abroad. The OncAlert Oral Cancer product line comprises two tests — the OncAlert Lab ... |
| 11.07.2016 | Vigilant Biosciences Lands $5M Series B-2 | FORT LAUDERDALE, FL, Developer of solutions announced the successful completion of a $5 million round of financing through its Series B2 offering. >> Click here for more funding data on Vigilant Biosciences >> To export Vigi... |
| 11.07.2016 | Vigilant Biosciences Completes $5M Series B2 Financing | Vigilant Biosciences, Inc., a Ft. Lauderdale, FL-based developer of solutions that aid in the early detection and intervention of cancer, completed a $5m Series B2 financing. Backers included White Owl Capital Partners, venVelo and others, ... |
| 02.03.2015 | Vigilant Biosciences Raises $5.5 Million In Series B Funding | Miami, Florida based Vigilant Biosciences is a leading high-tech healthcare company that focuses on early detection and intervention of cancer. Vigilant Biosciences has raised $5.5 million in Series B funding from White Owl Capital Partners... |
| 25.02.2015 | Vigilant Biosciences Closes $5.5M in Series B | MIAMI, FL, Leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the successful completion of a $5.5 million Series B round. >> Click here for more funding data on ... |
| 24.02.2015 | Vigilant Biosciences Completes $5.5M Series B Funding | Vigilant Biosciences, Inc., a Miami, Florida-based provider of solutions for the early detection and intervention of cancer, completed a $5.5m Series B round of funding. Backers included White Owl Capital Partners, venVelo, the Florida Inst... |
| 26.03.2014 | Rinse-and-spit test kit company gets $2.3M to develop an early oral cancer screening | The company is developing a low-cost kit for assessing a person’s risk of oral cancer before any lesions appear in the mouth. The kit comprises a teaspoon of saline solution, a collection cup and a testing strip. A person swishes the soluti... |
Show more